Bright Peak Therapeutics
Bright Peak Therapeutics is a privately held, clinical-stage biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation platform, with lead candidate BPT567, a first-in-class PD1-IL18 immunoconjugate, in a Phase 1/2a trial for solid tumors.
- Company typePrivate
- Founded2018
- HeadquartersAllschwil, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bright Peak Therapeutics does
Bright Peak Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017/2018 by Vijaya Pattabiraman and Jeffrey Bode out of ETH Zurich, headquartered in Allschwil, Switzerland with US operations in Del Mar/San Diego, California. The company is developing a portfolio of next-generation multifunctional precision immunotherapies for the treatment of cancer and autoimmune diseases, anchored by its proprietary EDC (Engineered Donor Acceptor) chemical ligation platform that enables site-specific protein modification and construction of multi-mechanism biologics. Its lead clinical candidate, BPT567, is a first-in-class PD1-IL18 immunoconjugate that combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single molecule, and entered a Phase 1/2a clinical trial for solid tumors in late 2024.
The company is backed by a top-tier syndicate of life sciences investors and has raised approximately $232 million across a Series A (2020, $35M, led by Versant Ventures), Series B (2021, $107M, led by RA Capital), and Series C (2024, $90M, led by Johnson & Johnson Innovation – JJDC). Bright Peak is led by President & CEO Fredrik Wiklund, whose prior track record includes biotech IPOs at Celladon and Tercica and ~$1.15 billion in aggregate prior M&A transactions, and President of R&D Jon Wigginton MD, who previously led early clinical development of nivolumab/opdivo and the broader BMS immuno-oncology portfolio.
Bright Peak operates a pre-revenue business model typical of clinical-stage biotechs: it does not currently sell commercial products, has not disclosed pricing, and finances operations exclusively through equity capital. Its addressable end customers are oncology patients with solid tumors and patients with autoimmune diseases, served through pharmaceutical distribution channels post any future regulatory approval; today its investor base and strategic partners effectively substitute for customers, with Johnson & Johnson's strategic venture arm anchoring the latest financing round.
Bright Peak Therapeutics firmographics
Firmographics- Name
- Bright Peak Therapeutics
- Legal name
- Bright Peak Therapeutics AG
- Website
- https://brightpeaktx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Bright Peak Therapeutics is a privately held, clinical-stage biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation platform, with lead candidate BPT567, a first-in-class PD1-IL18 immunoconjugate, in a Phase 1/2a trial for solid tumors.
- Ownership category
- akta.pro rank
Bright Peak Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Bright Peak Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Allschwil
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Bright Peak Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Marketing channels1 record
Bright Peak Therapeutics product offering
Product offeringCore offering
Bright Peak Therapeutics develops next-generation multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation protein-engineering platform. Its lead product, BPT567, is a first-in-class PD1-IL18 immunoconjugate that combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single therapeutic molecule and is currently in Phase 1/2a clinical trials for solid tumors.
Product overview
Bright Peak Therapeutics is developing a portfolio of next-generation multi-functional immunotherapies using its proprietary protein engineering platform. The lead product is BPT567, a first-in-class PD1-IL18 immunoconjugate for solid tumors. The company is leveraging its cytokine immunotherapy platform to develop treatments for cancer and autoimmune diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- BPT567 BPT567 is Bright Peak's first-in-class PD1-IL18 immunoconjugate designed for the treatment of solid tumors. It combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single therapeutic molecule and is currently in Phase 1/2a clinical trials. The candidate is intended for cancer patients with solid tumors, particularly those resistant to existing checkpoint inhibitors.
Quantifiable outcome
- Phase 1/2a clinical trial for BPT567 in solid tumors initiated in late 2024
Companies that use Bright Peak Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Bright Peak Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bright Peak Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Bright Peak Therapeutics competitors and assessment
Company assessmentDirect peers
- Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting with immune agonists. Most directly comparable to Bright Peak's approach of fusing immune-engaging payloads (IL-18) to targeting moieties (PD-1) in a single multifunctional molecule.
- Werewolf Therapeutics: Clinical-stage biotech with a proprietary INDUKINE platform that designs conditionally activated cytokine prodrugs for cancer immunotherapy. Directly comparable to Bright Peak's cytokine-based immunoconjugate approach, both companies engineer cytokines for improved therapeutic index in oncology.
- Cullinan Oncology: Clinical-stage immuno-oncology company developing multiple programs including cytokine-based therapies and checkpoint combinations. Highly comparable as a similarly-staged, publicly-traded clinical biotech with overlapping immuno-oncology focus; additionally, Jon Wigginton (Bright Peak's R&D President) was previously CMO at Cullinan.
- Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology, including a PD-1/PD-L1 bispecific (CTX-112) and other checkpoint-engaging molecules. Comparable in developing multifunctional immune-engaging antibody-based therapeutics for solid tumors.
- CytomX Therapeutics: Clinical-stage biotech with a Probody platform that uses masked/conditionally-activated antibodies for cancer. Comparable in developing engineered protein therapeutics designed to improve tumor selectivity and therapeutic index, though focused on masking rather than cytokine conjugation.
- Pyxis Oncology: Clinical-stage biotech developing antibody-drug conjugates and immunotherapies for cancer. Comparable as a similarly-staged biotech developing multifunctional antibody-based oncology therapeutics, with overlapping investor syndicate (RA Capital, Bayer).
- Janux Therapeutics: Clinical-stage biotech developing bispecific T-cell engagers for solid tumors. Comparable as a similarly-staged clinical biotech developing engineered multifunctional antibody constructs for oncology, with overlapping strategic investor interest (RA Capital).
- Harpoon Therapeutics: Clinical-stage biotech developing T-cell engagers (acquired by Merck in 2024 for ~$680M). Comparable as a developer of engineered multifunctional immune-engaging antibody therapeutics for solid tumors; provides a relevant M&A comp for Bright Peak given Merck/J&J strategic interest.
Broad incumbents
- Roche (Genentech): Large pharma with approved checkpoint inhibitor Tecentriq (anti-PD-L1) and extensive immuno-oncology pipeline including cytokine-based combinations and bispecifics. Relevant incumbent competing in Bright Peak's PD-1/IL-18 space with substantially greater resources.
- Bristol Myers Squibb: Large pharma with Opdivo (PD-1 inhibitor) approved and extensive checkpoint inhibitor/cytokine combination programs. Relevant incumbent and direct competitor; notably, Bright Peak's R&D President Jon Wigginton previously led early clinical development of Opdivo at BMS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bright Peak Therapeutics social profiles
Digital presenceBright Peak Therapeutics compliance and trust
Trust signalCompliance1 record
Bright Peak Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bright Peak Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Bright Peak Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bright Peak Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bright Peak Therapeutics
What does Bright Peak Therapeutics do?
Bright Peak Therapeutics develops next-generation multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation protein-engineering platform. Its lead product, BPT567, is a first-in-class PD1-IL18 immunoconjugate that combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single therapeutic molecule and is currently in Phase 1/2a clinical trials for solid tumors.
Is Bright Peak Therapeutics a public or private company?
Bright Peak Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bright Peak Therapeutics founded?
Bright Peak Therapeutics was founded in 2018. It employs 51 to 100 people.
Where is Bright Peak Therapeutics based?
Bright Peak Therapeutics is headquartered in Allschwil, Switzerland, in the Europe region.
Who are Bright Peak Therapeutics's main competitors?
Direct peers on record are Bolt Biotherapeutics, Werewolf Therapeutics, Cullinan Oncology, Compass Therapeutics, CytomX Therapeutics, Pyxis Oncology, Janux Therapeutics and Harpoon Therapeutics. Broad incumbents are Roche (Genentech) and Bristol Myers Squibb.
Does Bright Peak Therapeutics have an API?
No public API is recorded for Bright Peak Therapeutics.
What industry is Bright Peak Therapeutics in?
Bright Peak Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.